长效口服周制剂利培酮(LYN-005)治疗精神分裂症的3期试验
STARLYNG-1是一项在美国5个中心开展的非随机、开放标签3期试验,纳入83例临床稳定的精神分裂症或分裂情感性障碍患者,比较每周一次口服LYN-005与每日口服速释利培酮在稳态下的生物利用度。药代动力学分析(n=44)显示各主要终点几何均值比均达到预设标准,LYN-005提供持续释放且生物利用度与速释利培酮相似,患者保持临床稳定,未出现意外安全信号。
要点
- LYN-005每周一次口服给药,在精神分裂症患者中达到与速释利培酮相似的稳态生物利用度。
- 药代动力学主要终点(Cmin、Cmax、Cavg的几何均值比)均满足预设标准。
- 最常见治疗中出现的不良事件为胃肠道事件(67例中44例,66%),报告1例严重不良事件。
核心结论
- 每周一次口服LYN-005可在治疗浓度下持续释放利培酮,生物利用度与速释利培酮相似,患者保持临床稳定,未出现意外安全信号。
研究设计与样本
- 开放标签、非随机、3期试验,在美国5个中心纳入临床稳定的精神分裂症或分裂情感性障碍患者,住院5周(第9-13天除外)。
- 先经7天速释利培酮(2 mg或6 mg)导入期,后接受5次LYN-005(分别为15 mg或45 mg)每周一次口服,第1周补充半量每日速释利培酮。
- 研究注册号NCT05779241,已完成;83例入组,47例完成5周研究,药代动力学分析集n=44。
主要发现
- 药代动力学分析(n=44)中,LYN-005各剂量均观察到活性部分持续释放。
- 接受LYN-005的67例中,胃肠道治疗中出现的不良事件最常见(44例,66%),报告1例严重治疗中出现的不良事件。
临床怎么用
- LYN-005提供一种新型长效口服给药技术,可能有助于改善精神分裂症和分裂情感性障碍患者的用药依从性。
- 治疗期间需关注胃肠道不良事件,本研究中该类事件最常见。
局限性
- 开放标签、非随机设计,未设盲法。
- 样本量有限,药代动力学分析集仅44例,完成5周研究者47例。
- 研究期间患者住院(第9-13天除外),不能完全反映门诊真实世界用药情况。
- 研究设计未纳入有亲身经历者参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medication non-adherence and insufficiently managed disease worsen outcomes in people with schizophrenia. We aimed to compare the bioavailability of a long-acting oral weekly formulation of risperidone, LYN-005, with daily oral risperidone at steady state. METHODS: In this open-label, non-randomised, phase 3 trial, clinically stable participants with schizophrenia or schizoaffective disorder were enrolled from five sites across the USA while residing in an inpatient facility for 5 weeks (with the exception of days 9-13). After a 7-day run-in period with immediate-release risperidone (2 mg or 6 mg), participants received five doses of long-acting oral weekly LYN-005 (15 mg or 45 mg, respectively), with a supplemental half dose of daily immediate-release risperidone during week 1. Primary endpoints compared pharmacokinetic parameters of LYN-005 (minimum concentration [Cmin] at weeks 1 and 5, and maximum concentration [Cmax] and average concentration [Cavg] at week 5) with those of immediate-release risperidone on the last day of the run-in period. Prespecified primary endpoint criteria were geometric mean ratios for Cmin at week 1 and week 5 (90% CI ≥0·8), Cmax at week 5 (90% CI ≤1·25), and Cavg at week 5 (0·8 ≤90% CI ≤1·4). No people with lived experience were involved in the study design. This study was registered with ClinicalTrials.gov, NCT05779241, and has been completed. FINDINGS: Between April 13, 2023 and Dec 1, 2023, 83 participants were enrolled in the study (62 [75%] male and 21 [25%] female; 67 [81%] Black or African American, mean age 49·3 years [SD 11·5]), of whom 47 participants completed the 5-week study. In the pharmacokinetic analysis (n=44), sustained release of the active moiety was observed across all doses of LYN-005. Geometric mean ratios of LYN-005 versus immediate-release risperidone were 1·02 (90% CI 0·93-1·12) for Cmin at week 1, and 1·04 (90% CI 0·87-1·23), 0·84 (0·77-0·92), and 1·03 (0·93-1·13) for Cmin, Cmax, and Cavg, respectively, at week 5 and met predetermined criteria. In individuals taking LYN-005 (n=67), gastrointestinal treatment-emergent adverse events were most common (44 [66%] participants), with one serious treatment-emergent adverse event reported. INTERPRETATION: Weekly LYN-005 provided sustained release of risperidone at therapeutic concentrations with similar bioavailability to immediate-release risperidone. Patients remained clinically stable and no unexpected safety signals emerged. This offers a novel long-acting oral drug delivery technology for schizophrenia and schizoaffective disorder. FUNDING: Lyndra Therapeutics.
引用
- Citrome L, Nagaraj N, Traverso G, et al. Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial. Lancet Psychiatry. 2025. PMID: 40506209. doi:10.1016/S2215-0366(25)00135-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。